WHO Issues Guidelines on the Treatment of Children with MIS Associated with COVID-19
who.int
WHO issued updated guidelines on the management of multisystem inflammatory syndrome (MIS) in children associated with COVID-19 (MIS-C).
MIS-C is a rare but serious condition where children with COVID-19 develop inflammation affecting different organs of the body.
Children with this condition need specialized care, and may need to be admitted to intensive care. Although MIS-C is a serious condition, with the right medical care, children with this condition recover.
WHO’s updated guidelines recommend the use of corticosteroids in hospitalized children (aged 0-18 years) with this condition, in addition to supportive treatment and care.
This recommendation comes following the availability of three observational studies, pooling data from 885 patients in total.